Quest Diagnostics Incorporated (DGX) Downgraded by BidaskClub
Quest Diagnostics Incorporated (NYSE:DGX) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Bank of America Corporation upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their price target for the company from $111.00 to $118.00 in a research report on Tuesday, July 25th. Piper Jaffray Companies increased their price target on Quest Diagnostics to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, July 25th. Barclays PLC reiterated a “hold” rating and issued a $110.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 19th. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a $110.00 price target (up previously from $83.00) on shares of Quest Diagnostics in a research report on Thursday, July 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Quest Diagnostics currently has an average rating of “Buy” and a consensus target price of $110.72.
Quest Diagnostics (NYSE DGX) opened at 106.114 on Wednesday. Quest Diagnostics has a 52 week low of $79.12 and a 52 week high of $112.97. The firm has a market cap of $14.47 billion, a P/E ratio of 21.385 and a beta of 0.69. The company has a 50-day moving average of $109.16 and a 200 day moving average of $102.52.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same quarter last year, the company posted $1.34 EPS. Quest Diagnostics’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts predict that Quest Diagnostics will post $5.69 earnings per share for the current year.
WARNING: “Quest Diagnostics Incorporated (DGX) Downgraded by BidaskClub” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/09/quest-diagnostics-incorporated-dgx-downgraded-by-bidaskclub.html.
In other news, Director Jeffrey M. Leiden sold 1,304 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $108.73, for a total transaction of $141,783.92. Following the completion of the sale, the director now directly owns 6,296 shares of the company’s stock, valued at approximately $684,564.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Catherine T. Doherty sold 59,762 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $107.55, for a total value of $6,427,403.10. Following the sale, the senior vice president now directly owns 78,582 shares of the company’s stock, valued at $8,451,494.10. The disclosure for this sale can be found here. Insiders have sold a total of 61,362 shares of company stock valued at $6,600,758 over the last ninety days. Company insiders own 1.50% of the company’s stock.
Large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Quest Diagnostics by 2,638.3% in the first quarter. BlackRock Inc. now owns 15,362,418 shares of the medical research company’s stock worth $1,508,435,000 after buying an additional 14,801,397 shares during the period. State Street Corp increased its stake in Quest Diagnostics by 2.7% in the first quarter. State Street Corp now owns 6,918,900 shares of the medical research company’s stock worth $679,362,000 after buying an additional 180,690 shares during the period. Schroder Investment Management Group increased its stake in Quest Diagnostics by 8.3% in the first quarter. Schroder Investment Management Group now owns 2,188,114 shares of the medical research company’s stock worth $215,245,000 after buying an additional 167,246 shares during the period. Dimensional Fund Advisors LP increased its stake in Quest Diagnostics by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,022,107 shares of the medical research company’s stock worth $198,551,000 after buying an additional 99,153 shares during the period. Finally, Bank of America Corp DE increased its stake in Quest Diagnostics by 0.6% in the first quarter. Bank of America Corp DE now owns 1,887,303 shares of the medical research company’s stock worth $185,315,000 after buying an additional 11,399 shares during the period. 90.97% of the stock is owned by institutional investors.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.